Complete financial analysis of Pacific Biosciences of California, Inc. (PACB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pacific Biosciences of California, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Singapore Exchange Limited (S68.SI) Income Statement Analysis – Financial Results
- Frontier Energy Corporation (FRGY) Income Statement Analysis – Financial Results
- Empowered Products, Inc. (EMPO) Income Statement Analysis – Financial Results
- THECOO Inc. (4255.T) Income Statement Analysis – Financial Results
- AGF Management Limited (AGF-B.TO) Income Statement Analysis – Financial Results
Pacific Biosciences of California, Inc. (PACB)
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200.52M | 128.30M | 130.51M | 78.89M | 90.89M | 78.63M | 93.47M | 90.71M | 92.78M | 60.59M | 28.18M | 25.98M | 33.86M | 1.67M | 135.00K | 901.00K | 2.16M |
| Cost of Revenue | 147.74M | 79.27M | 71.65M | 46.33M | 56.32M | 53.53M | 58.81M | 46.55M | 39.33M | 37.19M | 21.76M | 25.04M | 20.83M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 52.78M | 49.04M | 58.86M | 32.57M | 34.58M | 25.10M | 34.66M | 44.16M | 53.45M | 23.40M | 6.42M | 940.00K | 13.03M | 1.67M | 135.00K | 901.00K | 2.16M |
| Gross Profit Ratio | 26.32% | 38.22% | 45.10% | 41.28% | 38.04% | 31.92% | 37.08% | 48.68% | 57.61% | 38.62% | 22.78% | 3.62% | 38.49% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 187.17M | 193.00M | 112.90M | 64.15M | 59.63M | 62.59M | 65.32M | 67.62M | 60.44M | 48.23M | 45.22M | 47.62M | 76.08M | 111.82M | 75.88M | 38.00M | 19.22M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 63.49M | 59.12M | 47.79M | 45.19M | 38.03M | 38.75M | 47.66M | 46.71M | 30.09M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 169.82M | 160.85M | 124.12M | 72.80M | 75.49M | 63.49M | 59.12M | 47.79M | 45.19M | 38.03M | 38.75M | 47.66M | 46.71M | 30.09M | 12.33M | 7.71M | 6.34M |
| Other Expenses | 30.26M | 7.64M | 93.00K | 2.06M | 1.02M | 848.00K | 516.00K | 103.00K | 364.00K | -478.00K | 728.00K | -127.00K | 0.00 | -104.00K | -84.00K | -102.00K | -67.00K |
| Operating Expenses | 387.25M | 353.85M | 237.02M | 136.95M | 135.12M | 126.08M | 124.44M | 115.40M | 105.63M | 86.26M | 83.96M | 95.28M | 122.79M | 141.91M | 88.21M | 45.71M | 25.55M |
| Cost & Expenses | 534.99M | 433.12M | 308.68M | 183.28M | 191.44M | 179.61M | 183.25M | 161.96M | 144.96M | 123.45M | 105.72M | 120.32M | 143.62M | 141.91M | 88.21M | 45.71M | 25.55M |
| Interest Income | 0.00 | 14.69M | 12.53M | 267.00K | 2.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 172.00K | 451.00K | 1.16M | 1.94M |
| Interest Expense | 14.34M | 14.69M | 12.53M | 267.00K | 2.61M | 2.42M | 2.92M | 3.23M | 2.93M | 2.83M | 2.48M | 0.00 | 287.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 26.53M | 17.32M | 11.59M | 9.30M | 9.95M | 7.22M | 8.44M | 3.88M | 3.68M | 4.22M | 5.65M | 6.65M | 5.80M | 5.16M | 4.10M | 2.99M | 1.58M |
| EBITDA | -277.28M | -282.24M | -250.76M | 38.97M | -71.58M | -92.92M | -80.83M | -67.27M | -25.09M | -59.11M | -71.17M | -87.52M | -103.29M | -135.01M | -83.97M | -41.82M | -21.81M |
| EBITDA Ratio | -138.28% | -231.62% | -136.44% | -129.71% | -109.50% | -127.36% | -95.51% | -74.15% | -55.84% | -97.55% | -252.54% | -337.49% | -308.07% | -8,068.94% | -62,197.04% | -4,641.73% | -1,008.51% |
| Operating Income | -334.47M | -304.82M | -178.16M | -104.39M | -100.55M | -100.99M | -89.78M | -71.24M | -29.13M | -62.85M | -77.54M | -94.34M | -109.76M | -140.23M | -88.07M | -44.81M | -23.39M |
| Operating Income Ratio | -166.80% | -237.58% | -136.51% | -132.31% | -110.62% | -128.44% | -96.06% | -78.54% | -31.40% | -103.73% | -275.16% | -363.08% | -324.12% | -8,377.18% | -65,237.04% | -4,973.25% | -1,081.41% |
| Total Other Income/Expenses | 16.31M | -9.43M | -96.71M | 133.79M | 16.41M | -1.58M | -2.41M | -3.13M | -2.56M | -3.31M | -1.75M | -127.00K | 368.00K | 68.00K | 367.00K | 1.06M | 1.87M |
| Income Before Tax | -318.16M | -314.25M | -274.87M | 29.40M | -84.13M | -102.56M | -92.19M | -74.38M | -31.70M | -66.16M | -79.29M | -94.47M | -109.39M | -140.17M | -87.70M | -43.75M | -21.52M |
| Income Before Tax Ratio | -158.67% | -244.92% | -210.61% | 37.27% | -92.57% | -130.44% | -98.63% | -81.99% | -34.16% | -109.19% | -281.37% | -363.56% | -323.03% | -8,373.12% | -64,965.19% | -4,856.16% | -994.82% |
| Income Tax Expense | -11.42M | -17.32M | -93.65M | -6.98M | -6.32M | 848.00K | -5.01M | 3.34M | -387.00K | 2.35M | 3.21M | 0.00 | -368.00K | -172.00K | -451.00K | -1.16M | -1.94M |
| Net Income | -306.74M | -296.93M | -181.22M | 29.40M | -77.82M | -102.56M | -92.19M | -74.38M | -31.70M | -66.16M | -79.29M | -94.47M | -109.39M | -140.17M | -87.70M | -43.75M | -21.52M |
| Net Income Ratio | -152.97% | -231.43% | -138.85% | 37.27% | -85.62% | -130.44% | -98.63% | -81.99% | -34.16% | -109.19% | -281.37% | -363.56% | -323.03% | -8,373.12% | -64,965.19% | -4,856.16% | -994.82% |
| EPS | -1.21 | -1.32 | -0.89 | 0.18 | -0.51 | -0.76 | -0.87 | -0.83 | -0.42 | -0.94 | -1.26 | -1.69 | -2.03 | -14.10 | -113.33 | -56.54 | -0.78 |
| EPS Diluted | -1.21 | -1.32 | -0.89 | 0.17 | -0.51 | -0.76 | -0.87 | -0.83 | -0.42 | -0.94 | -1.26 | -1.69 | -2.03 | -14.10 | -113.33 | -56.54 | -0.78 |
| Weighted Avg Shares Out | 253.63M | 224.46M | 203.62M | 172.96M | 152.53M | 134.95M | 105.68M | 89.15M | 75.61M | 70.48M | 62.78M | 55.73M | 53.87M | 9.94M | 773.84K | 773.84K | 27.74M |
| Weighted Avg Shares Out (Dil) | 253.63M | 224.55M | 204.14M | 174.97M | 152.53M | 135.09M | 105.68M | 89.15M | 75.61M | 70.48M | 62.78M | 55.73M | 53.87M | 9.94M | 773.84K | 773.84K | 27.74M |
Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
PacBio price target lowered to $6 from $7 at Scotiabank
PacBio to Present at Upcoming Investor Conferences
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y
Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript
Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
Source: https://incomestatements.info
Category: Stock Reports